Ratings by Leerink (Christopher Liu)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/6/2026 | Exelixis | EXEL | Downgrade | Market Perform (Outperform) |
56.70 (57.35) |
1.15% | Details | |
| 10/21/2025 | Exelixis | EXEL | Upgrade | Outperform (Market Perform) |
34.54 (56.70) |
64.16% | Details | |
| 3/26/2025 | Exelixis | EXEL | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/3/2025 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2024 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/16/2024 | Exelixis | EXEL | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/8/2023 | Relay Therapeutics | RLAY | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2023 | Exelixis | EXEL | New Coverage | Market Perform (N/A) |
20.25 (57.35) |
183.21% | Details | |
| 4/11/2022 | C4 Therapeutics | CCCC | Maintain | Outperform (N/A) |
|
Details | ||
| 2/18/2022 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2021 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/14/2021 | Nurix | NRIX | New Coverage | Outperform (N/A) |
28.79 (25.51) |
-11.39% | Details | |
| 10/14/2021 | Monte Rosa Therapeutics | GLUE | New Coverage | Market Perform (N/A) |
22.06 (14.11) |
-36.04% | Details | |
| 10/14/2021 | C4 Therapeutics | CCCC | New Coverage | Outperform (N/A) |
41.58 (3.76) |
-90.96% | Details | |
| 10/14/2021 | Arvinas Inc. | ARVN | New Coverage | Outperform (N/A) |
84.86 (7.50) |
-91.16% | Details |
